Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenegermin - Dompe Farmaceutici

Drug Profile

Cenegermin - Dompe Farmaceutici

Alternative Names: Cenegermin-bkbj; Nerve growth factor - Anabasis/Dompe; Oxervate; rhNGF; Sentinel

Latest Information Update: 06 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anabasis Pharma
  • Developer Dompe Farmaceutici; Ospedale San Raffaele
  • Class Eye disorder therapies; Nerve growth factors; Neuroprotectants; Proteins
  • Mechanism of Action Nerve growth factor receptor agonists; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis; Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Keratitis
  • Phase II Dry eyes; Glaucoma; Retinitis pigmentosa

Most Recent Events

  • 30 Jul 2020 Cenegermin is market-licensed to Tanner Pharma Group
  • 30 Jul 2020 Registered for Keratitis in Israel prior to August 2020 and Australia, Canada, Switzerland (Ophthalmic)
  • 28 Jan 2020 No recent reports of development identified for phase-I development in Glaucoma in USA (Ophthalmic, Drops)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top